Home / Research Library / Compound Research
BPC-157 is a synthetic peptide of 15 amino acids (GEPPPGKPADDAGLV) that its developers describe as a fragment of a larger protein found in human gastric juice. Almost everything known about it comes from rodent and cell-culture experiments; the published human data amount to three small pilot reports, none with a control group. It is not an FDA-approved drug, and in Australia it is listed in Schedule 4 of the Poisons Standard.1,2,3,4
This overview explains what the peptide is, what the studies actually reported, how much weight the human evidence can bear, and where BPC-157 sits under Australian scheduling and anti-doping rules. Every finding below is labelled with the model it came from, because in this literature that is the single most important detail.
The name stands for "body protection compound". In 1993, Predrag Sikirić and colleagues at the University of Zagreb described a gastric juice protein of about 40,000 Da that they called BPC, together with a 15-amino-acid fragment of it, BPC 157, which they considered essential for its activity.1 A later cell study describes the pentadecapeptide as "a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice".5 The material used in research is made by solid-phase peptide synthesis rather than extracted from gastric juice.6
Several other names in the literature refer to the same peptide, including PL 14736, PLD-116 and bepecin. A 2003 paper noted that it was then in clinical trials for inflammatory bowel disease under the Pliva codes PL 14736 and PLD-116.7,8
| Property | Value |
|---|---|
| Class | Synthetic linear peptide (pentadecapeptide, 15 residues) |
| Sequence (one-letter) | GEPPPGKPADDAGLV |
| Sequence (three-letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C62H98N16O22 (free peptide, as listed by PubChem) |
| Molar mass | 1419.5 g/mol (PubChem) |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
| Other names | PL 14736, PLD-116, PL-10, bepecin |
| Origin | Partial sequence of BPC, a protein described in human gastric juice; made synthetically for research |
Peptides are often supplied as salts, and PubChem also records a trifluoroacetate form of BPC-157, so the formula and mass on a given batch's documentation can legitimately differ from the free-peptide values above.8
The BPC-157 research literature is large but narrow in type. A 2025 systematic review in the HSS Journal screened 544 records published between 1993 and 2024 and included 36 studies on mechanism, musculoskeletal outcomes, metabolism and safety: 35 were preclinical and one was clinical.2 The main threads are below.
The earliest work framed BPC as part of a proposed "stomach–stress–organoprotection" response and tested the fragment against induced lesions in animals. The 1993 overview reported protective effects across many animal injury models and species after intraperitoneal, intragastric or local application, stated that no toxicity had been observed, and described its own findings in strong terms, as "a breakthrough in stress theory".1 These were the developers' own animal studies.
Musculoskeletal work drives most current interest. In a 2003 rat study, animals with a surgically transected Achilles tendon received BPC-157 or saline by intraperitoneal injection; the authors reported better biomechanical, functional and microscopic healing scores in the peptide groups over 14 days. In the same paper, BPC-157 had no effect on the growth of cultured tendocytes on its own but opposed the growth-inhibiting effect of the lipid-peroxidation product 4-hydroxynonenal.7
A 2011 cell study from Taiwan found that BPC-157 did not increase proliferation of rat tendon fibroblasts, but did increase their outgrowth from tendon explants, their survival under hydrogen-peroxide stress and their migration, alongside dose-dependent activation of the FAK–paxillin adhesion pathway.5 Summarising this body of work, the 2025 systematic review described improved functional, structural and biomechanical outcomes in preclinical models of muscle, tendon, ligament and bone injury.2
A 2017 study reported that BPC-157 increased vessel density in the chick chorioallantoic membrane assay and in endothelial tube-formation assays, sped the recovery of blood flow in a rat hind-limb ischaemia model, and increased expression and internalisation of the receptor VEGFR2 in human vascular endothelial cells, with activation of VEGFR2–Akt–eNOS signalling.9 A 2025 review likewise lists VEGFR2 and nitric oxide synthesis through the Akt–eNOS axis among the pathways BPC-157 activates in animal models.3 These mechanistic findings rest on cell, egg and rat models.
| Study | Model | What was reported |
|---|---|---|
| Sikirić et al., 1993 | Animal injury models (overview of the group's work) | Protective effects across induced-lesion models; no toxicity observed |
| Staresinic et al., 2003 | Rat, transected Achilles tendon; cultured tendocytes | Better biomechanical and functional healing scores than saline controls |
| Chang et al., 2011 | Rat tendon fibroblasts in vitro | More outgrowth, survival under oxidative stress and migration; proliferation unchanged |
| Hsieh et al., 2017 | Chick embryo membrane, human endothelial cells, rat hind-limb ischaemia | Pro-angiogenic effects linked to VEGFR2–Akt–eNOS signalling |
| He et al., 2022 | Rats and beagle dogs | Elimination half-life under 30 minutes; rapid breakdown to small fragments |
Put plainly: very weak. No randomised controlled trial of BPC-157 has been published. What exists is three pilot reports from private clinics, all led by the same first author and all published in the journal Alternative Therapies in Health and Medicine, and none with a control group:
Studies designed like these cannot separate a drug effect from placebo response, natural recovery or recall bias, and two participants cannot establish safety. The authors of a 2025 narrative review called the human data "exceedingly sparse" and observed that all published BPC-157 studies report positive or beneficial effects, which they said suggests possible publication bias.3
A phase I safety and pharmacokinetics study of an oral BPC-157 tablet (PCO-02), planned to enrol 42 healthy volunteers in 2015–16, is registered on ClinicalTrials.gov. Its status is listed as unknown and no results have been posted.13 Until controlled trials report results, the accurate summary is that BPC-157's effects in people are unknown.
The first published pharmacokinetic study of BPC-157 was done in animals. In rats and beagle dogs, the elimination half-life of intact BPC-157 was under 30 minutes, bioavailability after intramuscular injection was about 14–19% in rats and 45–51% in dogs, and radiolabelled peptide was broken down rapidly into small fragments and amino acids that were excreted mainly in urine and bile.6 In humans, the only data come from the two-person intravenous report, which a 2025 review notes found plasma concentrations back at baseline within 24 hours.3 The 2025 systematic review found that preclinical safety studies showed no adverse effects across several organ systems, and also that "no clinical safety data were found".2
Regulators have pointed to the same gap. The US FDA's list of bulk drug substances that may present significant safety risks in compounding states that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization", and that the agency "has identified no, or only limited, safety-related information". On the version of that page current as of 22 April 2026, BPC-157 sits in the table of substances previously in category 2 whose nominations were withdrawn by the nominators.14 Reviews published in 2025 describe BPC-157 as a category 2 substance, which reflected the earlier listing.2,3 Neither status is an approval.
For anyone searching "BPC 157 Australia", the regulatory position is set by the Poisons Standard, not by how a product is labelled. In the Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, which commenced on 1 June 2026, BPC-157 is listed in Schedule 4 (prescription-only medicines) and in Appendix D, clause 5, the table of poisons that "must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription)".4
The instrument also states that scheduling is implemented through state and territory legislation, and that the labelling exemption for poisons packed and sold solely for laboratory use "does not extend to controls on supply".4 What that means in practice depends on the jurisdiction and the purpose; our guide to whether research peptides are legal in Australia works through it. Titan Peptides supplies BPC-157 for laboratory research only.
In sport, the 2026 WADA Prohibited List names BPC-157 as an example in class S0, non-approved substances: pharmacological substances with no current approval by any governmental health authority for human therapeutic use, prohibited at all times, in and out of competition.15 Our article on peptides and the WADA Prohibited List covers the classes in more detail.
Because the evidence is so lopsided, it helps to ask the same five questions of every paper, press release or claim:
BPC-157 is most often discussed alongside a very different peptide derived from thymosin beta-4. For how the two compare, see BPC-157 vs TB-500 compared, and for the other compound's literature, our TB-500 and thymosin beta-4 research overview.
BPC-157 is a synthetic peptide of 15 amino acids with the sequence GEPPPGKPADDAGLV. Researchers at the University of Zagreb described it in 1993 as a fragment of a larger protein, called body protection compound, that they isolated from human gastric juice. It has been studied mainly in rodent and cell-culture models and is not an FDA-approved drug.
BPC stands for body protection compound, the name its developers gave to a protein of roughly 40,000 daltons that they reported isolating from human gastric juice. BPC-157 is the 15-amino-acid fragment of that protein which they described as essential for its activity. The peptide used in research is made by chemical synthesis rather than extraction.
Only in three small pilot reports without control groups: a retrospective knee-pain chart review of 16 patients, a single-arm interstitial cystitis study of 12 women and a two-person intravenous safety study. None can show whether BPC-157 has any effect in people. A phase I trial registered in 2015 has posted no results.
In humans they are essentially uncharacterised. The pilot reports described no adverse events, but they involved between two and 16 people with no comparison group. Animal safety studies reported no adverse effects across several organ systems, while the US FDA says it has no, or only limited, safety information and has flagged possible immunogenicity and impurity risks.
In the June 2026 Poisons Standard, BPC-157 is listed in Schedule 4, prescription-only medicines, and in Appendix D, clause 5, which covers poisons that must not be possessed without authority, such as a legal prescription. Scheduling is implemented through state and territory legislation, so the practical position depends on the jurisdiction and the purpose.
Yes. The 2026 WADA Prohibited List names BPC-157 as an example in class S0, non-approved substances, which are prohibited at all times, both in and out of competition. S0 covers pharmacological substances that have no current approval from any governmental health authority for human therapeutic use and are not addressed elsewhere on the List.
Two peptides that are often mentioned together but have nothing structurally in common. A side-by-side look at where BPC-157 and TB-500 come from, what studies reported, and where each sits under Australian and WADA rules.
TB-500 and thymosin beta-4 are not the same molecule. This overview explains the fragment, the full-length protein most studies used, the thin human data, and the Australian and WADA position.
What the TGA, the June 2026 Poisons Standard, the Therapeutic Goods Act and customs law actually say about peptides, "research use only" labels, importing and advertising in Australia.
